- PharmEasy is expected to raise Rs 2,400 crore via a discounted rights issue aimed at repaying its debt to Goldman Sachs.
- API Holdings, PharmEasy’s parent company, will issue new stock at Rs 5 per share, while the Manipal Group is predicted to invest approximately Rs 1,000 crore for an 18% stake.
- The novel fundraising round may occur at a valuation between $500-600 million, markedly down from its previous valuation of $5.6 billion in 2021.
Menu
